Defibrotide

Related by string. defibrotide * * *

Related by context. All words. (Click for frequent words.) 68 defibrotide 65 Tavocept 64 Virulizin R 64 Dacogen injection 63 Amrubicin 63 phase IIa clinical 63 phase IIb clinical 62 OPAXIO 62 FOLOTYN 62 perifosine 62 Proxinium TM 62 Fibrillex TM 62 Severe VOD 61 teduglutide 61 MOZOBIL 61 Icatibant 61 Evoltra 61 dacetuzumab 61 Cinryze TM 61 ularitide 60 pralatrexate 60 TREANDA 60 Cinryze ™ 60 Traficet EN 60 MGCD# [001] 60 clofarabine 60 PRT# 60 TORISEL 60 ADVEXIN 60 SNT MC# 60 Virulizin ® 60 decitabine 60 vidofludimus 60 maribavir 60 elacytarabine 60 C1 INH 59 TRISENOX 59 obatoclax 59 PEG INTRON 59 forodesine 59 Targretin 59 relapsed multiple myeloma 59 INCB# [002] 59 amrubicin 59 MYLOTARG 59 HuMax CD4 59 TEMODAL 59 Sym# 59 methylnaltrexone 59 Tamibarotene 59 Amigal 59 YONDELIS 59 Hepatocellular Carcinoma HCC 59 Phase 1b 59 EOquin 59 JAK inhibitor 59 aflibercept 59 ofatumumab 59 PXD# 59 mRCC 58 IRESSA 58 sapacitabine 58 XGEVA 58 hepatocellular cancer 58 metastatic renal cell carcinoma 58 Catena ® 58 OncoVEX GM CSF 58 FOLOTYN ® 58 axitinib 58 Amitiza 58 Taxotere ® 58 TELCYTA 58 CALGB # [002] 58 PROMACTA 58 Soliris TM eculizumab 58 Azedra 58 elotuzumab 58 oral RSD# 58 Cx# [002] 58 NXL# 58 Genasense ® 58 atacicept 58 BiovaxID 58 satraplatin 58 tocilizumab 58 Velcade bortezomib 58 AP# [003] 58 Aloxi injection 58 Phase 2a trial 58 eculizumab 58 Azixa 58 BARACLUDE R 58 elesclomol 58 FTY# 58 PEG SN# 58 Nimotuzumab 58 romidepsin 58 Novartis Zometa 58 imetelstat 58 Yondelis ® 58 SUTENT 58 alvimopan 58 RhuDex ® 58 confirmatory Phase III 58 palifosfamide 58 Vectibix 58 INCB# [001] 58 glufosfamide 58 CR# vcMMAE 58 EndoTAG TM -1 58 AQ4N 58 IRX 2 57 ELACYT 57 iclaprim 57 Phenoptin 57 palonosetron 57 Angiox R 57 TYZEKA 57 Cethrin 57 PrevOnco 57 eltrombopag 57 Folotyn 57 blinatumomab 57 Cloretazine R VNP#M 57 CMV disease 57 lubiprostone 57 azacitidine 57 talactoferrin 57 Phase Ib 57 Actimmune R 57 rilonacept 57 Phase 2b trial 57 Alzhemed TM 57 IL# PE#QQR 57 elinogrel 57 angiogenesis inhibitor 57 otelixizumab 57 ponatinib 57 lomitapide 57 pradefovir 57 Mycamine 57 telbivudine 57 alvespimycin 57 HRPC 57 ThermoDox R 57 Pirfenidone 57 Phase Ib II 57 Fludara 57 nitazoxanide 57 Actemra 57 rNAPc2 57 MYDICAR ® 57 HER2 positive metastatic breast 57 Nexavar sorafenib 57 mapatumumab 57 OvaRex ® MAb 57 Symadex 57 Alpharadin 57 sunitinib malate 57 drug ISA# 57 LymphoStat B 57 epratuzumab 57 valopicitabine 57 Cimzia ® 57 ILLUMINATE 57 fidaxomicin 57 OXi# 57 MEPACT 57 invasive candidiasis 57 Neurodex 57 lupus nephritis 57 oral ridaforolimus 57 lumiliximab 57 refractory angina 57 Ambrisentan 57 EFAPROXYN 57 Azilect ® 57 trabectedin 57 placebo controlled clinical 57 CYT# 57 Phase 2b 57 CoFactor 56 EGFR inhibitors 56 Akt inhibitor 56 picoplatin 56 Aplidin 56 entinostat 56 OHR/AVR# 56 HGS ETR1 56 TASQ 56 Ventavis 56 teriflunomide 56 LEUKINE 56 Angiox 56 Diabetic Macular Edema 56 AA Amyloidosis 56 velafermin 56 pomalidomide 56 vandetanib 56 Cloretazine R 56 Everolimus 56 APF# 56 terlipressin 56 silodosin 56 ZOLINZA 56 CEQ# 56 recurrent glioblastoma multiforme 56 LEVADEX 56 Tarceva TM 56 canakinumab 56 cancer vaccine Norelin 56 Zerenex 56 tivozanib 56 TRIOLEX 56 chronic ITP patients 56 tanespimycin 56 HuMax EGFr 56 AEG# 56 huC# DM4 56 BRIM2 56 CBLC# 56 Mepact 56 daclizumab 56 menadione 56 Rescula 56 Augment Injectable 56 enzastaurin 56 Revlimid lenalidomide 56 ThermoDox ® 56 PROSTVAC TM 56 bardoxolone 56 Gleevec imatinib mesylate 56 romiplostim 56 posaconazole 56 ganetespib 56 cinacalcet HCl 56 refractory CLL 56 randomized Phase IIb 56 Torisel 56 Increlex ® 56 palifermin 56 randomized Phase III 56 CA4P 56 Perifosine 56 voreloxin 56 REVLIMID 56 TELINTRA 56 tipranavir 56 CINOD 56 ITAX 56 ongoing Phase 1b 56 ASA# 56 ASCO GI 56 PROCHYMAL 56 BRIM3 56 Dapagliflozin 56 atherothrombotic events 56 Removab 56 post menopausal osteoporosis 56 CD3 monoclonal antibody 56 ecallantide 56 Raptiva ® 56 gastrointestinal stromal tumors GIST 56 Natalizumab 56 PREOS 55 micafungin 55 pertuzumab 55 invasive fungal infections 55 pivotal Phase III 55 acute HAE attacks 55 Fx #A 55 eniluracil 55 Plicera 55 Voraxaze ™ 55 YONDELIS R 55 adult chronic ITP 55 vismodegib 55 Pazopanib 55 riociguat 55 cobiprostone 55 HoFH 55 ISENTRESS 55 Panzem 55 Neulasta ® 55 ZYBRESTAT fosbretabulin 55 UPLYSO 55 HuLuc# 55 deferiprone 55 Alocrest 55 HGS# 55 Phase III clinical 55 celgosivir 55 Cleviprex TM clevidipine 55 SCCHN 55 Stimuvax R 55 Clevudine 55 PD LID 55 Cellegesic 55 AEZS 55 recurrent GBM 55 pharmacokinetic PK study 55 RGB # 55 Bezielle 55 relapsed ovarian cancer 55 REMICADE ® 55 BAY #-# 55 Irinotecan 55 APOPTONE 55 Gemzar ® 55 relapsed SCLC 55 Cimzia ® certolizumab pegol 55 Opexa 55 HUMIRA 55 volociximab 55 Civacir 55 tosedostat 55 Marqibo 55 BRAF inhibitor 55 depsipeptide 55 EVEREST II 55 BARACLUDE ® 55 Increlex R 55 PSN# [002] 55 Satraplatin 55 lucinactant 55 MAGE A3 ASCI 55 Troxatyl 55 GvHD 55 Bicifadine 55 TG MV 55 Protelos 55 GRN#L 55 Microplasmin 55 sorafenib Nexavar 55 Hexvix 55 Cloretazine 55 Diamyd ® 55 HuMax CD# 55 CIMZIA ™ 55 L BLP# 55 Phase 2a 55 oral FTY# 55 PCK# 55 zanolimumab 55 Telatinib 55 relapsed refractory multiple myeloma 55 cilengitide 55 chemotherapy induced neutropenia 55 cediranib 55 ARIKACE 55 HspE7 55 Dasatinib 55 Xanafide 55 panitumumab 55 APTIVUS 55 ZYBRESTAT 55 CINV 55 Aplidin R 55 SinuNase 55 XL# [003] 55 DU #b 55 dose escalation clinical 55 diabetic neuropathic pain 55 CCX# 55 EchoCRT 55 evaluating tivozanib 55 GED aPC 55 sorafenib tablets 55 Phase IIB 55 oral mucositis 55 sJIA 55 bazedoxifene 54 bone metastases 54 ALN RSV# 54 BiTE antibody 54 recurrent herpes labialis 54 Ozarelix 54 Avastin bevacizumab 54 ocrelizumab 54 Erlotinib 54 Tanespimycin 54 rFIXFc 54 antithrombotics 54 lintuzumab 54 reslizumab 54 NUEDEXTA 54 Kepivance 54 INT# [002] 54 Herceptin trastuzumab 54 Phase Ib clinical 54 ONCASPAR 54 CINTREDEKIN BESUDOTOX 54 tramiprosate 54 antifungal therapy 54 goserelin 54 MDV# 54 SILENOR TM 54 ACZ# 54 superficial bladder cancer 54 Allovectin 7 R 54 deforolimus 54 pseudobulbar affect PBA 54 MEK inhibitors 54 MAXY G# 54 ruxolitinib 54 Reolysin 54 clinical pharmacology studies 54 LY# [003] 54 investigational monoclonal antibody 54 HQK 54 entecavir 54 NEUPOGEN 54 KRN# 54 Oncophage vitespen 54 seliciclib 54 ImmunoVEX HSV2 54 Campath ® 54 ATIR 54 gefitinib 54 Ceflatonin 54 Clolar 54 EOquin TM 54 Aviptadil 54 IV Busulfex 54 mertansine 54 clevidipine 54 everolimus 54 ISTODAX 54 Insegia 54 Fludara ® 54 Sandostatin LAR Depot 54 Xyrem ® 54 SABCS 54 trastuzumab 54 DDP# 54 Clavis Pharma 54 Adhibit 54 HGS ETR2 54 MGCD# [002] 54 Altastaph 54 Mimpara 54 Cethromycin 54 Tolvaptan 54 biologic therapy 54 Gentium 54 OMAPRO 54 Nexavar ® 54 PDE4 inhibitor 54 MEK inhibitor 54 LibiGel ® 54 investigational drug 54 PREOS R 54 trastuzumab emtansine T DM1 54 cutaneous T cell 54 HCD# [002] 54 delafloxacin 54 Taxotere R 54 monotherapy 54 HCV 54 Atiprimod 54 mCRC 54 anticancer compound 54 BR.# 54 Bortezomib 54 talabostat 54 CYPHER Stent 54 CIMZIA TM 54 Tarceva erlotinib 54 MNTX 54 docetaxel Taxotere ® 54 Ketotransdel 54 pexiganan 54 SPRYCEL ® 54 Solesta 54 APPRAISE 54 prostate cancer CRPC 54 Bazedoxifene 54 apricitabine 54 ENMD 54 ProLindac 54 XL# XL# 54 EXPAREL ™ 54 Allovectin 7 ® 54 Urocidin 54 thalidomide Thalomid 54 Restanza 54 AZILECT R 54 bendamustine 54 PLX cells 54 phase IIa 54 relapsed MM 54 Angiolix 54 Vilazodone 54 linaclotide 54 cell lymphoma CTCL 54 PEGylated interferon beta 1a 54 Onrigin 54 anticancer agent 54 vascular disrupting agent 54 Pixuvri 54 VAPRISOL 54 hepatitis C HCV 54 antiplatelet agent 54 oropharyngeal candidiasis 54 BCX# 54 tafamidis 54 Rilonacept 54 NATRECOR R 54 phase 2a 54 Arcalyst 54 Ceflatonin R 54 OZURDEX ® 54 Valortim R 54 HCV protease inhibitor 54 haematological malignancies 54 AVN# [001] 54 vinorelbine 53 R sorafenib tablets 53 chronic HBV 53 interferon gamma 1b 53 pediatric acute lymphoblastic 53 Dextofisopam 53 Triolex 53 thymalfasin 53 efalizumab 53 BrachySil TM 53 isavuconazole 53 Cimzia R 53 brentuximab vedotin 53 Dalbavancin 53 Exelixis XL# 53 CD# antibody [001] 53 proteasome inhibitor 53 pafuramidine 53 Actemra tocilizumab 53 Vasovist 53 chemotherapy induced 53 Hepsera 53 RH1 53 antiangiogenic therapy 53 SCH # 53 brivaracetam 53 ADVEXIN therapy 53 Boceprevir 53 tezampanel 53 HCV infected 53 ixabepilone 53 Prestara 53 chronic HBV infection 53 Phase #/#a trial 53 gastrointestinal stromal tumors 53 belinostat 53 heterozygous FH 53 Gleevec resistant 53 Onalta 53 Mipomersen 53 relapsing multiple sclerosis 53 severe oral mucositis 53 randomized Phase 2b 53 daptomycin 53 NOXAFIL 53 dextromethorphan quinidine 53 ALN TTR# 53 rALLy clinical trial 53 Phase III 53 Hycamtin 53 temsirolimus 53 Behcet uveitis 53 ozarelix 53 ONTARGET 53 Noxafil 53 galiximab 53 anti EGFR antibody 53 anticancer therapy 53 sunitinib 53 Aloxi 53 ECTRIMS 53 Phase #/#a 53 PDX pralatrexate 53 Octreolin 53 EGS# 53 AEGR 53 Preotact 53 Phase Ib study 53 RDEA# 53 Annamycin 53 Telbivudine 53 casopitant 53 Perforomist ™ Inhalation Solution 53 BiTE antibody MT# 53 Firazyr 53 Hydroxyurea 53 Dacogen decitabine 53 Phase #b/#a clinical 53 humanized anti 53 Temsirolimus 53 TNFerade 53 bone metastasis 53 Viramidine 53 metastatic RCC 53 Imprime PGG 53 Vidofludimus 53 Pivotal Phase III 53 calcineurin inhibitors 53 Arixtra 53 PRISTIQ 53 B CLL 53 oral Xeloda 53 Raptiva R 53 Rezular 53 Randomized Phase 53 Genasense 53 invasive aspergillosis 53 ACAPODENE 53 anticancer therapies 53 Romiplostim 53 PREZISTA r 53 Phase 2a clinical 53 CAPHOSOL 53 Panzem R NCD 53 peginterferon 53 Ranolazine 53 Zavesca ® 53 Proquin XR 53 SERMs 53 TRO# 53 liposomal formulation 53 Reverset 53 investigational therapies 53 BEXXAR 53 selective androgen receptor modulator 53 IMPACT IMmunotherapy 53 pharmacokinetic PK 53 ganaxolone 53 adecatumumab 53 Aflibercept 53 Lenocta 53 castration resistant prostate cancer 53 ORENCIA ® 53 refractory multiple myeloma 53 SinuNase TM 53 oral deforolimus 53 EGFR tyrosine kinase inhibitors 53 epigenetic therapies 53 assessing T DM1 53 Soliris eculizumab 53 standard chemotherapy regimen 53 TheraSphere 53 SUPPRELIN R LA 53 Chemophase 53 Maribavir 53 LHRH antagonist 53 Lubiprostone 53 Factor VIIa 53 FVIIa 53 multiple myeloma MM 53 BCIRG 53 metaglidasen 53 Myocet 53 Certican 53 elvucitabine 53 bosutinib 53 Granulocyte Colony Stimulating Factor 53 R roscovitine 53 mycophenolate mofetil 53 Golimumab 53 phase IIb 52 Kuvan R 52 SPIRIT IV 52 VALSTAR 52 Trastuzumab 52 hereditary deficiency 52 SEPET TM 52 CINQUIL 52 phase IIb trial 52 cangrelor 52 Campath 52 noninfectious uveitis 52 bexarotene 52 Aloxi R 52 bortezomib Velcade 52 oncology indications 52 Bendamustine 52 neratinib 52 Cimzia TM 52 Elotuzumab 52 visilizumab 52 Debio 52 leukemia ALL 52 Treanda 52 Zavesca r 52 virus HCV protease inhibitor 52 FavId 52 BCR ABL inhibitors 52 PRTX 52 AMD# [003] 52 leukemia CLL 52 laquinimod 52 metastatic hormone refractory 52 ToGA 52 TKM ApoB 52 HER2 positive breast cancer 52 imatinib mesylate 52 Talabostat 52 IFN α 52 mitogen activated ERK kinase 52 Serdaxin 52 Evoltra ® 52 budesonide foam 52 TroVax ® 52 SEBIVO 52 refractory gout 52 subcutaneous formulation 52 NeuroStar TMS Therapy 52 antithrombotic therapy 52 Carfilzomib 52 MICARDIS ® 52 papillary renal cell carcinoma 52 TBC# 52 carfilzomib 52 xanthine oxidase inhibitor 52 castrate resistant prostate cancer 52 favorable pharmacokinetic profile 52 hereditary antithrombin deficiency 52 TransVax TM 52 crofelemer 52 antibody MAb 52 pegylated interferon alpha 52 Combidex 52 Phase III Clinical Trial 52 Octreotide 52 IPLEX 52 BEMA TM Fentanyl 52 Viprinex 52 Tarceva 52 6R BH4 52 Doxil ® 52 liver metastases 52 factor Xa inhibitor 52 relapsing remitting multiple sclerosis 52 receptor tyrosine kinase inhibitor 52 relapsing remitting MS RRMS 52 oral prodrug 52 anti angiogenic agents 52 Archexin 52 Ixempra 52 amifostine 52 SYCREST 52 Oracea ® 52 PROSTVAC VF 52 CDP# 52 oxymorphone ER 52 acyclovir Lauriad ® 52 INTELENCE 52 XYOTAX TM 52 Hedgehog Pathway Inhibitor 52 p# biomarker 52 IMiDs ® compound 52 Zenvia ™ 52 Vandetanib 52 Acute Radiation Syndrome ARS 52 Metastatic Melanoma 52 Pradefovir 52 Vicinium TM 52 Valortim ® 52 cutaneous T 52 oritavancin 52 Erbitux 52 #I TM# 52 T DM1 52 PROVENGE 52 Pixantrone 52 herpetic keratitis 52 octreotide implant 52 mTOR inhibitor 52 VEGF receptor inhibitor 52 Apaziquone 52 postoperative ileus 52 albinterferon alfa 2b 52 faropenem 52 Laquinimod 52 cSSSI 52 HDAC Inhibitor 52 targeting CD# 52 histamine dihydrochloride 52 Panzem R 52 rALLy trial 52 sipuleucel T 52 Pralatrexate 52 leukemia AML 52 Thalomid ® 52 #th Annual Interscience 52 metastatic melanoma 52 Sudhir Agrawal D.Phil 52 cetuximab Erbitux R 52 ZACTIMA 52 JAK1 52 Aurora kinase 52 Triapine R 52 CYC# 52 PKC# 52 bevacizumab Avastin 52 IGIV 52 Alemtuzumab 52 zoledronic acid Zometa 52 abiraterone 52 SUTENT ® 52 allogeneic stem cell 52 relapsed leukemia 52 Acute Myeloid Leukemia AML 52 Aptivus ® 52 INGN 52 CCR9 antagonist 52 PROSTVAC ® 52 antiangiogenic 52 Tocosol Paclitaxel 52 pazopanib 52 diabetic gastroparesis 52 Cotara 52 adefovir 52 SUCCEED trial 52 rilpivirine 52 Lixivaptan 52 DEFLUX 52 nucleoside analogue 52 MyVax R 52 Yondelis 52 treat dysmenorrhea 52 PNH patients 52 pan HDAC inhibitor 52 radiation sensitizer 52 Hsp# Inhibitor 52 SHPT 52 CAELYX 52 radezolid 52 ARRY 52 LUX Lung 52 VA# [002] 52 INC# 52 Voreloxin 52 dalbavancin 51 denosumab 51 Simulect 51 Liprostin 51 personalized immunotherapy 51 metastatic colorectal cancer 51 thrombolytic agent 51 Allovectin 7 51 diabetic nephropathy 51 XmAb# 51 Cytolin ® 51 Evicel 51 Linaclotide 51 Corlux 51 Ophena TM 51 Cancidas 51 ceftazidime 51 erlotinib 51 Phase IIb clinical trials 51 PEG interferon 51 viral kinetics 51 nilotinib 51 acyclovir Lauriad R 51 OMNARIS Nasal Spray 51 Tarvacin 51 Sandostatin LAR 51 Glufosfamide 51 PROVENGE ® 51 paclitaxel poliglumex 51 CANCIDAS 51 Dr. McHutchison 51 IMiDs 51 HCV SPRINT 51 multicenter clinical 51 multicenter Phase 51 URG# 51 Degarelix 51 betrixaban 51 cMET 51 huN# DM1 51 erlotinib Tarceva ® 51 catheter occlusion 51 Anturol 51 OMP #M# 51 APTIVUS r 51 ASH Annual Meeting 51 dose escalation trial 51 Riquent 51 Eribulin 51 XIENCE V stent 51 NEUVENGE 51 somatostatin analogue 51 nucleoside analogues 51 randomized controlled Phase 51 Fablyn 51 NUVIGIL 51 AGILECT R 51 NCCTG 51 prucalopride 51 MAP# 51 IMGN# 51 Capesaris 51 Blinatumomab 51 baminercept 51 uric acid lowering 51 oral antiviral 51 unresectable liver cancer 51 tipifarnib 51 pegfilgrastim 51 pegylated liposomal doxorubicin 51 TroVax 51 Vicriviroc 51 Phase 1b trial 51 RSR# 51 paclitaxel eluting stents 51 Dyloject TM 51 TACI Ig 51 Vivaglobin 51 chronic HCV infection 51 SPIRIVA HandiHaler 51 Gelclair 51 Pemetrexed 51 T Pred 51 oral anticoagulant 51 Zybrestat 51 CLL8 51 ProLindac TM 51 relapsed AML 51 MT# MEDI 51 Quinamed 51 panitumumab Vectibix 51 Alvesco R 51 immunomodulatory 51 hepatocellular carcinoma 51 Xinlay 51 nucleoside analog 51 renal toxicity 51 Omalizumab 51 antitumor activity 51 Sorafenib 51 INTEGRILIN R 51 peginterferon alfa 2b 51 TTF Therapy 51 PNP inhibitor 51 BCG refractory 51 EORTC 51 Advagraf 51 HyQ 51 intravenous formulations 51 vicriviroc 51 immunomodulatory therapy 51 Japanese Encephalitis vaccine 51 SIR Spheres 51 ISA# [002] 51 VivaGel TM 51 S. aureus infections 51 Myelodysplastic Syndrome MDS 51 PANVAC VF 51 Resolute DES 51 HZT 51 CYT# potent vascular disrupting 51 cIAI 51 DASISION 51 HBeAg positive 51 Ventavis ® 51 recurrent glioma 51 Enablex 51 evaluable patients 51 Ferinject ® 51 Cloretazine ® 51 Phase III VISTA 51 CCR5 antagonist 51 recurrent ovarian cancer 51 Nanobody 51 REOLYSIN ® 51 MAb 51 SAR# [004] 51 Besivance 51 Phase III HEAT 51 ProSavin 51 Telaprevir 51 KRAS status 51 preclinical efficacy 51 nephrotoxicity 51 granisetron 51 Methylnaltrexone 51 CTAP# Capsules 51 lapatinib Tykerb 51 pain palliation 51 PSMA ADC 51 post herpetic neuralgia PHN 51 CIPN 51 null responder 51 Zoraxel 51 Entereg R 51 oral mTOR inhibitor 51 plasma kallikrein inhibitor 51 Aryplase 51 Vitaxin

Back to home page